Altimmune's (ALT) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT - Free Report) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

A number of other brokerages have also commented on ALT. William Blair began coverage on Altimmune in a report on Friday. They set a "market perform" rating on the stock. UBS Group began coverage on Altimmune in a report on Tuesday, November 12th. They set a "buy" rating and a $26.00 price target on the stock. Finally, Stifel Nicolaus began coverage on Altimmune in a report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $20.83.

Altimmune Stock Down 9.9 %

NASDAQ ALT traded down $0.66 during trading hours on Monday, hitting $5.99. The company had a trading volume of 2,626,613 shares, compared to its average volume of 2,252,356. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $12.35. The business has a fifty day simple moving average of $6.81 and a 200-day simple moving average of $7.20. The firm has a market cap of $426.04 million, a P/E ratio of -3.86 and a beta of 0.19.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. Equities analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. grew its holdings in Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after acquiring an additional 1,378,854 shares during the period. Geode Capital Management LLC boosted its position in shares of Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company's stock valued at $10,244,000 after purchasing an additional 74,194 shares during the period. Bellevue Group AG boosted its position in shares of Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company's stock valued at $6,817,000 after purchasing an additional 81,786 shares during the period. Northern Trust Corp boosted its position in shares of Altimmune by 5.7% in the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company's stock valued at $4,801,000 after purchasing an additional 35,918 shares during the period. Finally, Two Sigma Investments LP boosted its position in shares of Altimmune by 33.2% in the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company's stock valued at $4,364,000 after purchasing an additional 151,001 shares during the period. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.